Colistin

Overview

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Associated Conditions

Ear infection bacterial
External ear infection NOS

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Comparative Study of Secondary Prophylaxis for SBP	2025/02/14	NCT06827756	Phase 4	Completed	Tanta University
Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection	2024/08/26	NCT06570850	Phase 4	Recruiting	Chiang Mai University
Colistin Dosage Prsonalization Approach	2024/06/25	NCT06472271	N/A	Recruiting	Mahmoud I Mostafa
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii	2023/06/28	NCT05922124	Phase 4	Not yet recruiting	Rambam Health Care Campus
Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial	2023/01/19	NCT05689229	Phase 3	Completed	Beni-Suef University
The Effect of Curcumin Against Colistin-induced Nephrotoxicity	2022/11/14	NCT05613361	Phase 3	Recruiting	October 6 University
Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection	2022/10/19	NCT05586815	Phase 4	Recruiting	Mahidol University
Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation	2022/09/15	NCT05542446	Phase 4	Terminated	St. Anne's University Hospital Brno, Czech Republic
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients	2022/03/15	NCT05279586	Early Phase 1	UNKNOWN	Madonna Magdy Fahmy
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections	2022/02/28	NCT05258851	Phase 3	Terminated	King Faisal Specialist Hospital & Research Center

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Colistin Sulfate Tablets	北京市燕京药业有限公司	国药准字H11020474	化学药品	片剂	1/14/2020
Colistin Sulfate Tablets	江苏联环药业股份有限公司	国药准字H32021260	化学药品	片剂	8/10/2020

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

FDA Grants QIDP Status to Venus Remedies' Novel Antibiotic VRP-034 for Bloodstream Infections

3 months ago

Venus Remedies' investigational antibiotic VRP-034 has received Qualified Infectious Disease Product designation from the FDA for treating bloodstream infections, providing benefits including priority review and extended market exclusivity.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access